These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 29958564)

  • 1. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
    Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
    Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally.
    Kassim AA; DeBaun MR
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):532-541. PubMed ID: 38066894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
    Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
    Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility.
    Aslam HM; Yousuf S; Kassim A; Iqbal SM; Hashmi SK
    Bone Marrow Transplant; 2018 Nov; 53(11):1390-1400. PubMed ID: 29728697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
    Krishnamurti L; Kharbanda S; Biernacki MA; Zhang W; Baker KS; Wagner JE; Wu CJ
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1270-8. PubMed ID: 18940682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Alvarez M; Pierini A; Simonetta F; Baker J; Maas-Bauer K; Hirai T; Negrin RS
    Front Immunol; 2020; 11():614250. PubMed ID: 33488624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good engraftment after reduced intensity targeted busulfan-based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies.
    Klink M; Felber M; Zeilhofer U; Hauri-Hohl M; Schmugge M; Drozdov D; Güngör T
    Pediatr Blood Cancer; 2024 Jul; 71(7):e30988. PubMed ID: 38613166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
    Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
    Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative Matched Sibling Donor Hematopoietic Cell Transplantation in Children and Adolescents with Sickle Cell Disease.
    Guilcher GMT; Monagel DA; Nettel-Aguirre A; Truong TH; Desai SJ; Bruce A; Shah RM; Leaker MT; Lewis VA
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1179-1186. PubMed ID: 30772511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.
    Hsieh MM; Fitzhugh CD; Tisdale JF
    Blood; 2011 Aug; 118(5):1197-207. PubMed ID: 21628400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
    Hsieh MM; Kang EM; Fitzhugh CD; Link MB; Bolan CD; Kurlander R; Childs RW; Rodgers GP; Powell JD; Tisdale JF
    N Engl J Med; 2009 Dec; 361(24):2309-17. PubMed ID: 20007560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
    Bhatia M; Jin Z; Baker C; Geyer MB; Radhakrishnan K; Morris E; Satwani P; George D; Garvin J; Del Toro G; Zuckerman W; Lee MT; Licursi M; Hawks R; Smilow E; Baxter-Lowe LA; Schwartz J; Cairo MS
    Bone Marrow Transplant; 2014 Jul; 49(7):913-20. PubMed ID: 24797180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.